Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Pass Above Two Hundred Day Moving Average – What’s Next?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $44.26 and traded as high as $44.27. Global X Genomics & Biotechnology ETF shares last traded at $43.86, with a volume of 5,529 shares trading hands.

Global X Genomics & Biotechnology ETF Trading Up 0.9%

The company has a market cap of $47.27 million, a price-to-earnings ratio of -18.53 and a beta of 1.22. The firm’s fifty day simple moving average is $46.82 and its 200 day simple moving average is $44.25.

Global X Genomics & Biotechnology ETF Dividend Announcement

The company also recently announced a dividend, which was paid on Wednesday, January 7th. Investors of record on Tuesday, December 30th were paid a dividend of $0.5912 per share. The ex-dividend date was Tuesday, December 30th. This represents a dividend yield of 259.0%. Global X Genomics & Biotechnology ETF’s payout ratio is presently -26.50%.

Institutional Trading of Global X Genomics & Biotechnology ETF

Hedge funds and other institutional investors have recently bought and sold shares of the business. IFP Advisors Inc boosted its position in shares of Global X Genomics & Biotechnology ETF by 20.8% during the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after acquiring an additional 489 shares in the last quarter. Creative Financial Designs Inc. ADV raised its position in shares of Global X Genomics & Biotechnology ETF by 4.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after acquiring an additional 481 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new stake in Global X Genomics & Biotechnology ETF during the fourth quarter worth approximately $575,000. Smartleaf Asset Management LLC lifted its stake in Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after purchasing an additional 4,615 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after purchasing an additional 12,105 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.